Trial reportFrontiers in pharmacology2026
A two-phase randomized study of oliceridine versus sufentanil for gastrointestinal endoscopy.
Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oliceridine is a novel G protein-biased μ-opioid receptor (MOR) agonist. It provides analgesic effects and reduces opioid-related adverse events (ORAEs). It has shown good efficacy in acute pain management. However, compared with traditional opioids, its optimal dosage and safety in gastrointestinal endoscopy have not been clearly established. We aimed to determine the 95% effective dose (ED Methods: This two-phase study was designed to evaluate the clinical effective dose and clinical safety of oliceridine. In the first phase, we used the modified Dixon's up-and-down method to determine the ED Results: In the first phase, we determined the ED Conclusion: At doses derived from a sequential dose-finding design, oliceridine combined with propofol was associated with a lower observed incidence of respiratory depression and modestly faster recovery compared with sufentanil during gastrointestinal endoscopy in low-risk patients. Given the methodological limitations of dose estimation and the limited power for safety outcomes, these findings should be interpreted cautiously and warrant confirmation in larger studies. Clinical Trial Registration: Identifier ChiCTR2500095827.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.